DiversiTrials
Arab Board for Clinical Research
MENASA Clinical Research Summit
Habibis United Research
Sincere Thanks for Hosting and Endorsing the DiversiTrials and Habibis United Research Meeting at the Congressional Office.
Dear Dr. Lalani and Team,
I hope this message finds you well. On behalf of DiversiTrials and Habibis United Research, I want to express our deepest gratitude to you and your entire team for endorsing and hosting the recent meeting at your office in Sugar Land, TX, on August 19, 2024. The event, which focused on championing minority equity in clinical trials, was an overwhelming success, thanks in large part to your support and hospitality.
The meeting was very well received, drawing significant attendance both in person and virtually. The level of engagement from participants underscored the importance of this crucial topic. Your commitment to addressing the disparities in clinical research, particularly as they affect Arab Americans, South Asian Americans, and other underrepresented populations, is inspiring. Your leadership in this area is helping to pave the way for more inclusive and equitable healthcare outcomes for all.
We sincerely appreciate the time, effort, and resources that you and your team dedicated to making this event a success. Your endorsement of this cause amplifies the impact of our collective work and highlights the critical role that legislative and community leaders play in advancing health equity.
As we look to the future, we are excited about the prospect of continuing our collaboration. We are particularly looking forward to the upcoming Middle Eastern, North Africans, and South Asians (MENASA) Summit, organized by DiversiTrials and Habibis United Research, to be held on April 19, 2025, at the United Way of Greater Houston, TX. With your ongoing support, we are confident that we can continue to make meaningful strides in advocating for the inclusion of all communities in clinical trials.
Thank you once again for your partnership and for championing the cause of minority equity in clinical trials. We greatly look forward to working together on future initiatives.
Warm regards,
Hadi Danawi